Savarese et al. included 94 randomized trials in their meta-analysis and found that long-term (29 weeks or more) use of DPP-4 inhibitors (not specified) was associated with a significantly higher risk of heart failure (relative risk 1.158, 95% CI: 1.011-1.326, P = 0.034), but this was not observed in short-term users (relative risk 0.668, 95% CI: 0.318-1.400, P = 0.285) [6]. Here, DPP4 is linked to heart failure.